Impact of Metformin on Thyroid Function and Autoimmune Antibody in Type 2 Diabetic Patients With Hashimoto’s Thyroiditis

Read full text Summarise with VIRAT
Authors: Guangmin Chen, Yanxiang Shao, Qicong Liu, Rui Zhang, Juan Wang, Houdi Zhou
Cited by: 0
References: 31

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background Hashimoto’s thyroiditis is the most common autoimmune disease, characterized by elevated thyroid peroxidase antibodies (TPOAb) and thyroid globulin antibodies (TgAb). Recent studies have shown that metformin has therapeutic effects in various autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, and inflammatory bowel disease. Methods This open‐label, single‐center, randomized controlled trial aims to evaluate the efficacy of metformin in modulating the autoimmune response in patients with Hashimoto’s thyroiditis and delaying disease progression in Type 2 diabetes patients. The trial recruited 60 Type 2 diabetic patients with Hashimoto’s thyroiditis. These patients were randomly assigned to two groups: the metformin group ( n = 30) received metformin treatment (initial dosage: 0.5 g/day, gradually increased to 1.5 g/day within 1 month), while the control group ( n = 30) was treated with other oral hypoglycemic drugs. After 6 months, the volume of the thyroid, TPOAb, thyroglobulin antibodies (TgAb), tumor necrosis factor‐α (TNF‐α), interferon‐γ (INF‐γ), interleukin‐2 (IL‐2), soluble Fas (sFas), and sFas ligand (sFas‐L) were evaluated in both groups. Results Six months post‐therapy, the levels of TPOAb, TgAb, and thyroiditis score in the metformin group decreased significantly, with normal thyroid volume (all p < 0.01), and all the indices were lower than those in the control group (all p < 0.05). In contrast, the control group showed no significant changes in the levels of TPOAb, TgAb, thyroiditis score, or thyroid volume. Compared to the control group, the metformin group exhibited significantly lower levels of TNF‐α, INF‐γ, and IL‐2, as well as reduced expression of Fas and sFas‐L in the blood (all p < 0.05). Conclusion Metformin hinders the advancement of Hashimoto’s thyroiditis in individuals with Type 2 diabetes, and its mode of action may be linked to the suppression of the Fas/Fas‐L‐mediated apoptotic pathway.

Fields of Study & Subjects

Thyroid Disorders and Treatments Systemic Lupus Erythematosus Research Adrenal Hormones and Disorders

Publication details

Journal / source
International Journal of Endocrinology
Volume
2026
Issue
1
Pages
5542077
Publication date
1 January 2026
Language
EN